ClinicalTrials.gg
RecruitingNCT07668596EXSFNUpdated Jul 17, 2026

Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults

An interventional study of Sulforaphane-rich Broccoli Sprout Extract and High Intensity Interval Treadmill Running in Immunometabolism, Mitochondrial Function, Bioenergetics and Inflammation, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2026, registered Jun 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Inflammation by University of British Columbia — 2 open to participants now, 2 under way, none of them phase 3. Inflammation · University of British Columbia.

Planned enrollment
8th of 13
20 · median 31
Started
2026
with 1 other
No phase
8 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Inflammation by University of British Columbia, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 15th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

2 of the 15 studies in Inflammation by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 19 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Inflammation by University of British Columbia, or all of them as a file.
02

Study summary

The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.

03

Conditions studied

  • Immunometabolism
  • Mitochondrial Function, Bioenergetics
  • Inflammation

Keywords

  • Nutraceuticals
  • Exercise
  • Bioenergetics
  • Immunometabolism
  • Inflammation
  • High intensity interval training
04

Who can participate

Ages eligible
19 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged between 19 and 35 years
  • not a current smoker
  • physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)

Exclusion criteria

Exclusion Criteria:

  • a history of cardiometabolic diseases or respiratory diseases (e.g., , asthma, diabetes, coronary artery disease)
  • currently following a ketogenic diet
  • (BMI) over 30 kg/m2
  • unable to read or communicate in English
  • having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks
  • having donated more than 0.5 L of blood within the last 4 weeks
  • currently pregnant
  • have to high intensity exercise (assessed using the CSEP Get Active Questionnaire)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sulforaphane Supplementation Only

    In this intervention, participants will consume commercially available broccoli sprout extract capsules daily for 4 days (20 mg/day) . Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.

    Dietary Supplement: Sulforaphane-rich Broccoli Sprout Extract

  • Active comparator
    Exercise Only

    In this intervention, participants will complete supervised exercise sessions daily for 4 days. The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace. Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.

    Other: High Intensity Interval Treadmill Running

  • Experimental
    Sulforaphane Supplementation and Exercise

    In this intervention, participants will consume commercially available broccoli sprout extract tablets daily for 4 days. In addition, participants will complete supervised exercise sessions daily for 4 days. The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace. Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.

    Dietary Supplement: Sulforaphane-rich Broccoli Sprout Extract · Other: High Intensity Interval Treadmill Running

Interventions

  • Dietary supplementSulforaphane-rich Broccoli Sprout Extract

    Broc Elite Plus stabilized sulforaphane capsules from Mara Labs

  • OtherHigh Intensity Interval Treadmill Running

    4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.

06

What researchers measure

Primary outcomes

  1. Change in peripheral blood mononuclear cell oxygen consumption rate

    OCR will be measured using a Seahorse Analyzer before and after each 4-day intervention

    Time frame: 0-4 days

Secondary outcomes

  1. TNF-alpha secretion from LPS-stimulated whole blood

    TNF-alpha secretion from LPS-stimulated whole blood will be measured via ELISA before and after each 4-day period

    Time frame: 0-4 days

  2. Change in percentage of classical monocytes before and after the 6-week intervention

    The percentage of classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention

    Time frame: 0-4 days

  3. Change in percentage of intermediate monocytes before and after the 4-day intervention

    The percentage of intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention

    Time frame: 0-4 days

  4. Change in percentage of non-classical monocytes before and after the 4-day intervention

    The percentage of non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention

    Time frame: 0-4 days

  5. Change in TLR-4 expression on classical monocytes before and after the 4-day intervention

    TLR-4 expression on classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.

    Time frame: 0-4 days

  6. Change in TLR-4 expression on intermediate monocytes before and after the 4-day intervention

    TLR-4 expression on intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.

    Time frame: 0-4 days

  7. Change in TLR-4 expression on non-classical monocytes before and after the 4-day intervention

    TLR-4 expression on non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention

    Time frame: 0-4 days

  8. Change in white blood cell counts before and after the 4-day intervention

    White blood cell counts will be measured using a hematology analyzer at baseline and after the 4-day intervention

    Time frame: 0-4 days

  9. TNF-alpha secretion from PolyIC-stimulated whole blood

    TNF-alpha secretion from PolyIC-stimulated whole blood will be measured via ELISA before and after each 4-day period

    Time frame: 0-4 days

  10. Change in peripheral blood mononuclear cell extracellular acidification rate before and after the 4-day period

    PBMC ECAR will be measured using a Seahorse Analyzer at baseline and after the 4-day intervention

    Time frame: 0-4 days

  11. Change in PBMC mitotracker green staining before and after the 4-day period

    PBMC mitotracker green will be measured using flow cytometry before and after the 4-day intervention period

    Time frame: 0-4 days

  12. Change in PBMC mitoSOX red staining before and after the 4-day period

    PBMC mitoSOX red will be measured using flow cytometry before and after the 4-day intervention period

    Time frame: 0-4 days

  13. Change in PBMC mitochondrial respiration before and after the 4-day intervention period

    PBMC mitochondrial respiration will be measured using high-resolution respirometry before and after the 4-day period

    Time frame: 0-4 days

07

Study locations

1 of 1 sites recruiting
  • Reichwald Health Sciences Centre
    Kelowna, British Columbia V1V 1V7, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared to ensure the privacy and confidentiality of participants, in accordance with ethical guidelines and data protection regulations. Additionally, this was not included in the informed consent, which did not cover data sharing or address potential risks of re-identification.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 21 months is above that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 25, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668596
Responsible party
Hashim Islam (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Jun 25, 2026
Start date
Mar 1, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Hashim Islam Principle Investigator, Ph.D
Contact
hashim.islam@ubc.ca
250-807-9122

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion